关注
Brian Claggett
Brian Claggett
Harvard Medical School
在 partners.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Spironolactone for heart failure with preserved ejection fraction
B Pitt, MA Pfeffer, SF Assmann, R Boineau, IS Anand, B Claggett, ...
New England Journal of Medicine 370 (15), 1383-1392, 2014
26472014
Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
MA Pfeffer, B Claggett, R Diaz, K Dickstein, HC Gerstein, LV Køber, ...
New England Journal of Medicine 373 (23), 2247-2257, 2015
25322015
Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction
SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ...
New England Journal of Medicine 381 (17), 1609-1620, 2019
18672019
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
SD Solomon, JJV McMurray, B Claggett, RA de Boer, D DeMets, ...
New England Journal of Medicine 387 (12), 1089-1098, 2022
13392022
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial
MA Pfeffer, B Claggett, SF Assmann, R Boineau, IS Anand, N Clausell, ...
Circulation 131 (1), 34-42, 2015
9542015
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction
E Kraigher-Krainer, AM Shah, DK Gupta, A Santos, B Claggett, B Pieske, ...
Journal of the American College of Cardiology 63 (5), 447-456, 2014
8502014
Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis
SB Seidelmann, B Claggett, S Cheng, M Henglin, A Shah, LM Steffen, ...
The Lancet Public Health 3 (9), e419-e428, 2018
7652018
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis
H Uno, B Claggett, L Tian, E Inoue, P Gallo, T Miyata, D Schrag, ...
Journal of clinical Oncology 32 (22), 2380, 2014
6462014
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
SD Solomon, B Claggett, EF Lewis, A Desai, I Anand, NK Sweitzer, ...
European heart journal 37 (5), 455-462, 2016
5552016
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis …
M Vaduganathan, BL Claggett, PS Jhund, JW Cunningham, JP Ferreira, ...
The Lancet 396 (10244), 121-128, 2020
5422020
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
M Vaduganathan, KF Docherty, BL Claggett, PS Jhund, RA de Boer, ...
The Lancet 400 (10354), 757-767, 2022
4902022
Declining risk of sudden death in heart failure
L Shen, PS Jhund, MC Petrie, BL Claggett, S Barlera, JGF Cleland, ...
New England Journal of Medicine 377 (1), 41-51, 2017
4812017
PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction
SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ...
N Engl J Med 381 (17), 1609-1620, 2019
4782019
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
AS Desai, JJV McMurray, M Packer, K Swedberg, JL Rouleau, F Chen, ...
European heart journal 36 (30), 1990-1997, 2015
4772015
Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone
AM Shah, B Claggett, NK Sweitzer, SJ Shah, IS Anand, L Liu, B Pitt, ...
Circulation 132 (5), 402-414, 2015
4672015
Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
LH Lund, B Claggett, J Liu, CS Lam, PS Jhund, GM Rosano, K Swedberg, ...
European journal of heart failure 20 (8), 1230-1239, 2018
4602018
Sacubitril/valsartan across the spectrum of ejection fraction in heart failure
SD Solomon, M Vaduganathan, B L. Claggett, M Packer, M Zile, ...
Circulation 141 (5), 352-361, 2020
4372020
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
JP Seferovic, B Claggett, SB Seidelmann, EW Seely, M Packer, MR Zile, ...
The lancet Diabetes & endocrinology 5 (5), 333-340, 2017
3912017
Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure
K Damman, M Gori, B Claggett, PS Jhund, M Senni, MP Lefkowitz, ...
JACC: Heart Failure 6 (6), 489-498, 2018
3792018
Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure
MR Zile, BL Claggett, MF Prescott, JJV McMurray, M Packer, JL Rouleau, ...
Journal of the American College of Cardiology 68 (22), 2425-2436, 2016
3752016
系统目前无法执行此操作,请稍后再试。
文章 1–20